SCA Pharmaceuticals Recalls Fentanyl Syringes Due to Sterility Concerns
SCA Pharmaceuticals is recalling fentanyl syringes because they may leak and lack assurance of sterility.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, which corresponds to a Severe severity score according to the rubric.
Plain-English summary
SCA Pharmaceuticals is recalling fentaNYL 10 mcg/mL PF in NS 1 mL Fill in 3 mL syringes (NDC# 70004-0229-05). The recall is due to a lack of assurance of sterility and the potential for the product to leak.
The affected lot is 20170512@19 with a beyond-use date of 8/10/2017. The product was distributed nationwide. This is a prescription-only medication.
Consumers and healthcare providers should stop using the recalled product and contact SCA Pharmaceuticals or their healthcare provider for instructions on how to return or dispose of the medication.
The recalled product
- Product
- fentaNYL 10 mcg/mL PF in NS 1 mL Fill in 3 mL syringe, Rx only, SCA Pharmaceuticals, 8821 Knoedl Ct Little Rock, AR 72205 --- NDC# 70004-0229-05
- Manufacturer
- SCA Pharmaceuticals
- Category
- Drug — Injectable
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lot: 20170512@19 BUD: 8/10/2017
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 30 recalled by SCA Pharmaceuticals under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 30 products in this recall →Related recalls
Same manufacturer · SCA Pharmaceuticals
See all →- HighSCA Pharmaceuticals Fentanyl-Bupivacaine Injectable Recall Due to Manufacturing Deviations
FDA (Drugs) · 2023-08-02
- ModerateFDA recalls Oxytocin product for low potency nationwide
FDA (Drugs) · 2023-05-03
- ModerateFentanyl Injection Syringes Recalled for Subpotent Active Ingredient
FDA (Drugs) · 2023-03-08
- ModerateNorepinephrine Injection Recalled Nationwide for Manufacturing Quality Deviations
FDA (Drugs) · 2022-05-11
- ModerateDrug recall: fentanyl and bupivacaine injectable solution manufacturing deviations
FDA (Drugs) · 2022-05-11
Same hazard · sterility
See all →- SevereK.C. Pharmaceuticals Recalls Target Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tri-MIX Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Semaglutide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Leader Advanced Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
Similar recalls
- SevereSCA Pharmaceuticals Recalls Fentanyl Syringes Due to Sterility Concerns
FDA (Drugs) · 2021-01-13
- SevereSCA Pharmaceuticals Recalls Fentanyl Injectable Bags Due to Sterility Concerns
FDA (Drugs) · 2017-06-07
- SevereSCA Pharmaceuticals Recalls Fentanyl Injection Bags Due to Sterility Concerns
FDA (Drugs) · 2017-06-07
- HighfentaNYL 1,250 mcg Injection Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2024-04-03
- HighFentanyl Injection Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2024-04-03
- SevereSCA Pharmaceuticals Recalls Phenylephrine Syringes Due to Sterility Concerns
FDA (Drugs) · 2017-11-08